Extended-spectrum beta-lactamase-producing pathogens in a children's hospital: A 5-year experience

Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah, PO Box 581289, Salt Lake City, UT 84158, USA.
American journal of infection control (Impact Factor: 2.33). 02/2009; 37(6):435-41. DOI: 10.1016/j.ajic.2008.09.019
Source: PubMed

ABSTRACT Pediatric infection with bacteria producing extended-spectrum beta-lactamases (ESBLs) has not been well described. We sought to determine the proportion of isolates producing ESBLs and the incidence of infection or colonization with these organisms in our tertiary care pediatric facility over 5 years. In addition, we sought to evaluate the characteristics of children affected.
We identified all Escherichia coli or Klebsiella spp cultured from children younger than 18 years of age at our facility between January 2003 and December 2007. Medical records were reviewed for affected children.
Of 2697 E coli, K pneumoniae, and K oxytoca cultured, 26 ESBL producers were isolated from 16 children. Rates of ESBL production among cultured isolates significantly increased, from 0.53% in the first half of the study period to 1.4% in the second. Incidence of a primary ESBL infection also increased significantly, from 0.14/10,000 patient encounters to 0.31/10,000. The majority of children infected or colonized with ESBL-producing organisms were those with chronic medical conditions, frequent hospitalizations, or a history of recurrent infection. However, 4 affected children were less than 5 months old and evaluated in an outpatient setting.
Rates and incidence of ESBL infection increased over the study period. Whereas most patients belonged to traditional risk groups for antibiotic-resistant infection, infants in the ambulatory setting were also affected, an at-risk population not previously described.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae present an ever-growing burden in the hospital and community settings, across all ages and demographics. Infections due to ESBL-containing pathogens continue to be associated with significant morbidity and mortality worldwide. With widespread empiric broad-spectrum β-lactam use creating selective pressure, and the resultant emergence of stable, rapidly proliferating ESBL-producing clones with continued horizontal gene transfer across genera, addressing this issue remains imperative. Although well characterized in adults, the epidemiology, risk factors, outcomes, therapies, and control measures for ESBL-producing bacteria are less appreciated in children. This analysis provides a brief summary of ESBL-producing Enterobacteriaceae in children, with a focus on recent clinical and molecular data regarding colonization and infection in nonoutbreak settings.
    Clinical Infectious Diseases 01/2015; DOI:10.1093/cid/civ020 · 9.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The production of β-lactamase is the most common mechanism of resistance to β-lactam antibiotics among gram-negative bacteria. Extended-spectrum β-lactamases (ESBLs) are capable of hydrolyzing most penicillins, extended-spectrum cephalosporins, and aztreonam, but their activity is suppressed in the presence of a β-lactamase inhibitor. Serious infections with ESBL-producing isolates are associated with high rates of mortality, making early detection and adequate medical management essential to ensure optimal patient outcomes. Much controversy has centered on the recommendations for testing and reporting of antibiotic susceptibility of potential ESBL-producing organisms. The latest version of the Clinical Laboratory Standards Institute (CLSI) susceptibility reporting guidelines, published in 2010, no longer advocates for phenotypic testing of ESBL-producing isolates. From newer studies demonstrating a correlation between organism minimum inhibitory concentration (MIC) and clinical outcome, along with pharmacokinetic/pharmacodynamic (PK/PD) modeling demonstrating the importance of the MIC to achieving therapeutic targets, the CLSI has assigned lower susceptibility breakpoints for aztreonam and most cephalosporins. The new guidelines recommend using the lower MIC breakpoints to direct antibiotic selection. This article reviews the microbiology and epidemiology of ESBLs, the recent change in CLSI susceptibility reporting guidelines for ESBLs, and the clinical and PK/PD data supporting the relationship between in vitro susceptibility and clinical outcome. Finally, considerations for antimicrobial selection when treating patients with infections caused by ESBL-producing organisms from various sources are discussed.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to determine the prevalence of extended spectrum beta-lactamase (ESBL) producing Klebsiella pneumoniae strains isolated from blood in children and their susceptibility to antimicrobial drugs commonly used in the therapy. The study was conducted at the Institute of Public Health of Vojvodina Province, Serbia, in a two-year period, from January 2009 to December 2010. A total of 424 non-duplicate strains were isolated from the blood of pediatric patients hospitalized in various wards in the Institute of Health Care of Children and Youth of Vojvodina Province. Fifty isolates of Klebsiella pneumoniae were reported. The frequency of isolation of Klebsiella pneumoniae was 27/222 (12.2%) and 23/202 (11.3%) isolates in 2009 and 2010, respectively. There was a high prevalence of ESBL-producing Klebsiella pneumoniae, 76% (38/50), and 17 isolates (44.7%) were multidrug resistant (MDR). Further drug resistance surveillance in hospitals and the molecular characterization of ESBL-positive isolates in our country is necessary.
    Archives of Biological Sciences 01/2012; 64(4):1339-1347. DOI:10.2298/ABS1204339M · 0.61 Impact Factor